Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment
Launched by NISHTAR MEDICAL UNIVERSITY · Mar 20, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • size of keloid1-5 cm,
- • on any site of the body,
- • duration less then five years and
- • baseline Vancouver scar score of more the or equal to 5
- Exclusion Criteria:
- • Pregnant or lactating women,
- • family history of keloids,
- • acromegaly, and
- • congestive cardiac diseases
Trial Officials
Dr. Aliya Akhtar, FCPS
Study Director
Nishtar Medical University
About Nishtar Medical University
Nishtar Medical University is a prestigious institution dedicated to advancing medical education, research, and healthcare in Pakistan. With a commitment to excellence, the university actively engages in clinical trials to explore innovative treatments and enhance patient care. By fostering collaboration among researchers, healthcare professionals, and academic institutions, Nishtar Medical University aims to contribute significantly to the scientific community and improve health outcomes through rigorous clinical research and ethical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multan, Punjab, Pakistan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
